Bortezomib (Btz) Dose Intensity Is the Strongest Predictor for Overall Survival (OS) in Mantle Cell Lymphoma (MCL) Patients (Pts) Not Considered for Transplantation, Receiving Frontline Btz Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Therapy in the Phase 3 LYM-3002 Study

Konference: 2014 56th ASH Annual Meeting - účast ČR

Kategorie: Maligní lymfomy a leukémie

Téma: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster

Číslo abstraktu: 4412

Autoři: MD Tadeusz Robak, PhD.; MD Huiqiang Huang, PhD; MD Jie Jin, PhD; MD Jun Zhu; Ting Liu; MD Olga S Samoilova; MD Halyna Pylypenko; Prof. Dr. Gregor Verhoef, Ph.D.; Noppadol Siritanaratkul; Evgenii Osmanov; Julia Alexeeva; Juliana Pereira, PhD; prof. MUDr. Jiří Mayer, CSc.; Xiaonan Hong; Yoshiharu Maeda; Lixia Pei, PhD; Brendan Rooney, PhD; MD Helgi van de Velde, PhD; Prof. MD Franco Cavalli, FRCP

Datum přednesení příspěvku: 8. 12. 2014